though studies of cell-mediated cytotoxicity to tissue culture cells infected with SFFVMuLV. Tumors are maintained by ascites transfer of 107 cells at weekly intervals in irradiated (800 rads) B6 mice. The B6 M-MuLV tumors were induced by intraperitoneal injection of 10 s plaque-forming units of M-MuLV into neonatal B6 mice. All tumors except B6FR~2 arose in female mice, and all were used in transplant generations 3-15.
Friend erythroleukemic spleen cells were obtained by perfusion with medium 199 of the massively enlarged spleens of mice infected 10-12 d earlier with 103.5 FFU of the appropriate FV strain. Cells obtained in this manner were 85-95% viable as judged by trypan blue exclusion. The target Friend erythroleukemic spleen cells (FEC) for the cytotoxic assay were obtained from the spleens of (C3H/HeJ × B6)F1 mice infected 10-12 d earlier with 10 s's FFU of NB-tropic FV.
Antisera. BALB/c anti-FV serum was prepared by intraperitoneal injection into 10-wk-old female BALB/c mice of 102 FFU of N-tropic FV followed by injection of increasing doses of NB-tropic FV (17) . B6 anti-FV serum was obtained after six intravenous injections of 10 s'~ FFU of NB-tropic FV into female B6 mice at bimonthly intervals. B6 anti-RBL-5 serum was prepared by hyperimmunization of 10-wk-old B6 mice with living RBL-5 cells according to the immunization schedule detailed in our previous publication (25) . Mice were bled from the tail vein in alternative weeks, and serum from each bleeding was pooled. Mice were reimmunized 3-4 d after bleeding.
Cytotoxic and Absorption Tests. Direct cytotoxic tests were performed, as previously described (25, 37) , by incubation of equal volumes (50 #1) of 2.5 × 10 s FEC, diluted antiserum and appropriately diluted rabbit serum (C source) at 37°C for 45 min. Viability counts were made in the presence of trypan blue. Preselected rabbit serum was used at a dilution of 1:5 or 1:7 in all tests with transplantable lymphoma cells (C control gave 10% lysis) and at a dilution of 1: 15 in all tests with FEC (C control gave 13% lysis).
Antibodies that react with helper F-MuLV determinants were removed from B6 anti-FV serum by absorption of 2 voi of antiserum, four-to sixfold more concentrated than that which gave 50% FEC lysis (generally a dilution of 1/20-1/40) with 1 vol of packed B6FR~2 cells at 4°C for 30 min. Cells were removed by centrifugation at 1,000 g for 10 rain, and this FMRpreabsorbed antiserum was then used for typing of Friend Erythroleukemia antigen by a second absorption test. B6FR~2-preabsorbed antiserum (50 pl) was absorbed a second time with a range of counted numbers of cells for 30 rain at 4°C, and the residual cytotoxic activity for FEC was determined in direct cytotoxic tests. Cytotoxicity is calculated according to the formula: (absorbed (percent lysis) -C)/100 -C.
Results
Serological Reactivities of Anti-FV Antisera. The Fv-2 resistance gene of B6 mice absolutely inhibits the induction of erythroleukemic colonies by FV (11), but only partially inhibits SFFV replication (15) . Thus, it follows that cytotoxic antibodies to SFFV-specific antigens might be produced in B6 mice. After hyperimmunization with NB-tropic FV, B6 mice produced antibodies cytotoxic for (C3H/He × B6)F1 FEC and for cells of the B6 F-MuLV lymphoma B6FR~2 (Fig. 1) . The sensitivity of B6FR~2 cells, as well as cells from several other primary or transplanted F-MuLV lymphomas, to lysis by B6 anti-FV serum was less than that of FEC. To distinguish a quantitative difference in the amount of antigen expressed by these two target cells from a qualitative difference in the determinants expressed, absorption experiments were carried out.
Absorption of B6 anti-FV serum with B6FRc~2 cells completely removed cytotoxic activity for B6FR~2 but not FEC (Fig. 1) . The reactivity of B6 anti-FV serum for B6FR¢~2 but not FEC, was also removed by absorption with SC-1 tissue culture cells productively infected with NB-tropic F-MuLV (Fig. 1) . Absorption with FEC, on the other hand, removed all cytotoxic activity for both target cells (Fig. 1) . To exclude the possibility that these results were due solely to the greater sensitivity of FEC to lysis, a second absorption of B6 anti-FV serum was carried out with B6FRd2 cells. Because no further decrease of cytotoxic activity for FEC was observed after this second absorption of B6 anti-FV serum (Fig. 1) , it is likely that antibodies present in B6 anti-FV antiserum recognize determinants restricted to FEC, as well as determinants expressed on both cells. Earlier serologic studies of the FMR antigen(s) indicated that the antigens detected on lymphoma and erythroleukemia cells were entirely cross-reactive (17) (18) (19) (20) (21) . Those studies differ from the present one in two important aspects: (a) anti-FV sera, which might be expected to recognize SFFV antigens, were prepared in Fv-2 s mice, primarily BALB/c (17, 20) ; and (b) when antisera were prepared in B6 mice, FMR MuLV lymphomas, which lack SFFV, were used for immunization (18, 19) . Therefore, we have tested two antisera, representative of earlier FMR-typing sera (17, 18) , in our test system. The data in Table I c anti-FV antisera by absorption with B6FR~2; these results are thus consistent with previous studies (17) (18) (19) . However, sera from two groups of FV-hyperimmunized B6 mice contain antibody cytotoxic for FEC that cannot be removed by absorption with B6FRc~2. It should be noted that absorptions of B6 or BALB/c anti-FV antisera were performed at dilutions of 1/30 or 1/20, respectively, so that results from Table I might be compared to results from earlier studies (20, 21) . However, later sera from 2 of the 10 individual BALB/c mice tested showed a residual cytotoxic activity specific for FEC when sera were absorbed at 1/7. This low titer antibody does not have the alloantigen reactivity described below and has not been further analyzed. The results presented thus far indicate that two cytotoxic antibodies are present in B6 anti-FV serum; one directed to determinants shared by FEC and B6FR~2, and the other directed to determinants expressed only on FEC.
.Analysis of B6 Anti-FV Serum by Absorption with Primary and Transplantable Mouse Tumors:
Serological Definition of Friend Erythroleukemia (FE) Antigen. The serological reactivities of B6 anti-FV antiserum were analyzed by quantitative absorption tests with a number of tumors. Cells from a spontaneous AKR thymoma absorbed no cytotoxic activity, whereas absorption with FMR lymphoma cells or tissue culture cells producing F-MuLV removed 40-50% of the cytotoxic activity for FEC (Fig. 2) . To exclude the possibility that the partial absorption shown by FMR tumors reflected a lower concentration of antigen expressed on these tumors compared with FEC, a second quantitative absorption experiment was performed with a number of FMR lymphomas using B6FRd2-preabsorbed B6 anti-FV antiserum. The results of this analysis, presented in Table II and Fig. 3 , indicate that a second absorption of B6FRc~2-preabsorbed serum with FMR lymphomas did not further reduce cytotoxicity for FEC. Erythroleukemias induced by SFFV, whether of FV or Rauscher virus origin, completely absorbed cytotoxic activity for FEC. This consistent pattern of reactivity suggests that a single antigenic system is detected by the cytotoxic activity of B6FRc~2- preabsorbed B6 anti-FV serum for FEC. We shall refer to the antigen detected by this test system as FE antigen to clearly distinguish it from other FV-related determinants.
We have examined the expression of FE antigen on a number of transplantable tumors of the mouse by quantitative absorption tests (Table III) . None of these tumors remove cytotoxic activity from FE typing serum, i.e. B6FRd~2-preabsorbed B6 anti-FV antiserum; therefore they do not express this antigen. From the known antigenic phenotypes of this panel of leukemia cells, we conclude that FE antigen is serologically unrelated to the previously defined cell surface alloantigens or MuLV-related antigens H-2, TL, Lyt series, Thy-l, PC. 1, Glx, G(RADA1), G(F_m,D), or G(AKSL2) (37) . In view of the syngeneic typing systemj i.e., B6 antiserum on (C3H × B6)F1 cells, and lack of serological cross-reactivity between FMR typing serum and naturally occurring MuLV (17, 18) , this result is not surprising.
Expression of FE Antigen on MuL V-Infected Tissue Culture Cells.
The ability of MuLV strains to induce FE antigen expression on tissue culture cells was determined by absorption of FE typing serum with productively infected cells (36) . Endogenous ecotropic or xenotropic MuLV strains do not induce the appearance of this determinant (Table IV) . Antigens induced by the two dualtropic viruses MCF 247 and Fr MCF-1, which were isolated from a preleukemic AKR thymus (38) and a F-MuLV lymphoma (23), respectively, do not react with FE typing serum. The failure of endogenous ecotropic, xenotropic, or MCF-recombinant MuLVs (23, 38) to absorb (31, 39) . Biological and biochemical studies have demonstrated that these lines carry only the SFFV genome and morphologically resemble the parental cell lines from which they were established (31, 39) . Results from quantitative absorption experiments indicate that the nonproducer cell SFFV-NRK expresses approximately the same quantity of FE antigen as FEC cells (Fig. 3) . Similar results were observed with the other two SFFV nonproducer cell lines (Table IV) . It should be noted that SFFV-NIH also apparently expresses the FMR determinant detected by unabsorbed B6 anti-FV serum because absorption of B6 anti-FV antiserum with SFFV-NIH removed all cytotoxic activity for FEC (Fig. 2) . A similar specification of FMR antigen(s) by the Abelson defective genome was observed in studies of Abelson MuLV nonproducer cells (25) . The serologic evidence presented so far defines a previously unrecognized viral cell-surface antigen of mouse leukemia, FE antigen. Expression of FE antigen is limited to erythroleukemias induced by, or cell lines infected with SFFV. tests with FE typing serum. Tissues of B6 and C57L mice uniformly typed negative for FE antigen expression. Bone marrow and spleen of BALB/c, DBA/2, SWR, and AKR mice were clearly positive; thymus, peripheral blood, and lymph node of these strains were negative (Fig. 4) . BALB/c and SWR, but not B6 mice, express FE on fetal liver; the absorptive capacity of this tissue is about threefold greater than of bone marrow (Fig. 4) . Adult liver or kidney was negative in these three strains. Direct cytotoxic tests with FE typing serum did not detect significant lysis of BALB/c or SWR fetal liver, bone marrow, spleen, thymus, or lymph node cells. The absorptive capacity of fetal liver from uninfected FE-positive mice is ----3% that of FEC; the absorptive capacity of bone marrow is ~1% that of FEC; and positive spleen cells from uninfected mice have ~0.2% the absorptive capacity of FEC. Thus, results from quantitative absorption experiments and direct cytotoxic tests are consistent with the expression of FE by a minor cell population present in bone marrow, fetal liver, and spleen. Because cell-surface expression of FE in uninfected mice is a characteristic of only certain differentiated tissues, it is appropriate to also describe this determinant as a differentiation antigen.
Expression of FE Antigen on Tissues of Uninfected

Genetic Control of FE Antigen in Uninfected Mice: Concordance of Antigen Expression with Inheritance of the Fv-2 s Virus Sensitivity Allele.
We have typed bone marrow of several inbred strains for expression of FE by quantitative absorption tests. Only mice of the C57-C58 family were negative; all other inbred strains express FE antigen on bone marrow (Table V) . This strain distribution profile is reminiscent of that observed for the Fv-2 locus (40) . Therefore, we have tested BALB/c × B6 recombinant inbred strains, i.e., the seven strains generated by Bailey (41) by inbreeding BALB/c × B6 Fz mice, for expression of FE antigen. Again, expression of FE antigen was concordant with inheritance of the Fv-2 s allele (Table V) (42) .
Four congenic strains that have substituted Fv-2 regions were tested for expression of FE antigen. The strains B10.C(47N) and B6.C-H-7 b were made by substitution of the BALB/c H-7 histocompatibility locus onto the respective C57BL/10 or B6 genetic backgrounds (43, 44) . Because H-7 is tightly linked to Fv-2, these strains also carry the (9) . The partially congenic D2.RB strain was constructed by three backcrosses to DBA from B6 with selection for Fv-U heterozygosity at each'generation (29) . Mice then were interbred, and Fv-2 "/r homozygotes used to establish the D2.RB line, which is in its 14th generation of inbreeding; D2.RB is ~87.5% DBA genetic background (R. Steeves, personal communication). Data from quantitative absorption tests of FE-antigen expression on bone marrow of parental and congenic strains, presented in Fig. 5 , indicate that "substitution of the Fv-2 region of B6 or C57BL/10 with that of BALB/c or SIM results in FE antigen expression; conversely, substitution of the Fv-2 region of DBA/2 with that of B6 results in the loss of expression. Participation of the H-7-histocompatibility antigens in this serological typing system is excluded because B6 and DBA mice do not differ at this locus (40) .
Discussion
The FE antigenic system identifies the second differentiation alloantigen that has been specifically associated with the defective transforming genome of a rapidly oncogenic MuLV. Absorption tests with FE typing serum establish that this immunogenetic system does not cross-react with previously described cell-surface antigens of mouse leukemia (37), induced by viral or cellular genes. The consistent appearance of FE in FV and Rauscher virus erythroleukemias and its absence from lymphomas of diverse origin support the designation of this determinant as an antigen of virally induced erythroleukemic differentiation. However, FE is not limited to erythroleukemias, but also appears on fibroblastoid cells carrying the SFFV genome, and on uninfected fetal liver, bone marrow, and spleen cells of Fv-2 s mice. Absorption experiments with B6 anti-FV antiserum indicated that SFFV nonproducer cells and FMR lymphoma cells share antigenic determinants. An analogous expression of FMR determinant(s) on Abelson virus nonproducer cells was noted in a previous study (25) . As both defective virus genomes share some gag but not env gene products with their respective helper viruses, proteins encoded by the gag region are logical candidates for FMR-bearing molecules. Previous work suggested that this might be the case (20) , however, more recent studies indicate env gene-products bear the FMR determinants (21) . The recent observation that FMR MuLV are more efficient for oncogenesis by, but not replication of, FMR-derived defective virus genomes (45, 46 ; Dr. D. Troxler, personal communication) may suggest the interaction of related molecular determinants in leukemogenesis by this family of MuLV. Further serological and biochemical analysis of the FMR antigenic system, which identifies such determinants, may clarify this point.
A conclusion consistent with the appearance of FE antigen on non-transformed SFFV-infected fibroblasts is that cell-surface expression of FE is programmed by SFFV rather than erythroleukemic differentiation per se. The simplest explanation for such a viral program is that SFFV encodes FE antigen, a proposition that can be substantiated only by biochemical identification of FE antigen. Accumulating evidence points to the recombinational origin of SFFV (24, 31, 39, 47) , and other pathogenic MuLVs (38, 48, 49) ; thus, it is possible that SFFV arose by recombination between exogenous helper MuLV and the cellular sequences encoding FE antigen. The initial appearance of erythroleukemia-inducing activity in FV after passage through Swiss mice (1), and in Rauscher virus after passage through BALB/c mice (50) is consistent with this hypothesis, because these two strains express FE antigen on uninfected hematopoietic tissue. Results from molecular hybridization experiments indicate that SFFV-specific nucleotide sequences can be detected in the DNA of uninfected mice; the appearance of these sequences in RNA shows a differentiative program similar to that described for FE antigen (Bernstein and Mak, personal communication) . It will be of interest to determine if the presence of such sequences in DNA or in RNA also shows genetic polymorphism.
The alternative explanation that FE antigen is universally encoded in mice and rats and induced by SFFV functions, has a precedent in the TL antigenic system (51) . TL antigen is a thymocyte differentiation antigen in some strains of mice; in other strains, which do not normally express this determinant, TL is an antigen of preleukemic and leukemic differentiation (37, 51) . Only TL-mice produce TL antibody (37) . In these regards, our observations on FE antigen parallel those on TL; however, no TL-inducing virus has yet been identified (37) .
The detection of FE antigen on a minor cell population present in bone marrow, fetal liver, and spleen suggests that this determinant is an alloantigen of primitive hematopoietic differentiation. Preliminary experiments indicate that FE antigen is expressed on some hematopoietic colony-forming cells. Because the active organs of erythropoiesis in the mouse are fetal liver, bone marrow, and spleen, and because expression of FE antigen shows a similar pattern of expression, it may also be expressed on primitive cells committed to erythroid differentiation. It is worth noting that the immunogenetic system that regulates transplantation of spleen colony-forming ceils has also been implicated in resistance to FV erythroleukemia (52) . Perhaps the FE antigen with its dual appearance on SFFV cells and hematopoietic colony-forming cells, is an antigen recognized by this unusual immunogenetic system.
Relevant to a discussion of the normal differentiative functions of the FE antigen is the observation that FE antigen appears to be controlled by the Fv-2 locus. Though all tests demonstrated cosegregation of FE with Fv-2 s, it is possible that FE is controlled by a gene in the Fv-2 region and not the susceptibility factor itself. Only more extensive genetic tests can clarify this point. The studies of Steeves et al. on the partially congenic D2.RB strain indicated that Fv-2 r has an inhibitory effect on SFFV replication but not on virus infection (15) . Blank and Lilly went on to make the surprising observation that the fully congenic DBA-Fv-2 ~/" genotype is apparently lethal in utero because no Fv-2 ~/" mice were recovered when 14th generation DBA-Fv-2 s/" heterozygotes were intermated (53) . The results of Axelrad et al., using B6 and B6.S strains, indicated that the primary effect of Fv-2 may be physiologic control of erythroid progenitor cell proliferation (16) . If Fv-2 s determines the presence of a cellsurface antigen as our results indicate, and if such an antigen were a necessary signal for hematopoietic proliferation and differentiation in certain genetic backgrounds, then genetic removal of such a determinant would half normal development. The unconventional inheritance patterns of the Gix antigen, an MuLV-related cell-surface structure, could be similarly interpreted to result from unfavorable cell-surface interactions in normal development (54, 55) . These two immunogenetic systems--Fv-2-controlled FE antigen and Gv-l-controlled Gxx antigen--provide evidence for a physiologic role of MuLV-related cell-surface antigens in normal development.
A possible role for FE antigen is that of a cell-surface signal or receptor involved in proliferation and differentiation of the erythroid pathway, perhaps as a critical determinant of the hematopoietic inductive microenvironment (56) . The control of FE antigen by SFFV or by Fv-2 s would thus reflect the fact that both viral and cellular genes control cell proliferation through a common mechanism. The observations ofAxelrad et al. (16) that erythroid burst-forming cells are more rapidly dividing in B6.S than in B6 mice (and thus more likely to be transformed), might lend support to this idea. Alternatively, FE antigen might function as a tissue-specific self-recognition structure. In such a ease, the failure of SFFV-infected cells to differentiate into erythroblastic colonies in Fv-2 r/r mice may result from a failure of self-recognition. The C57-C58 family of mice have apparently evolved alternative structures to effect the same result.
The FE antigenic system appears quite similar to that described for Abelson antigen (25). Each antigen is specified by a defective transforming genome of MuLV, though the tissue specificity of these two viruses is quite different. Each antigen is also a normal differentiation alloantigen of bone marrow, fetal liver, and spleen in uninfected mice of the strain from which the defective virus was first isolated. Each antigen is apparently controlled by a dominant sensitivity locus, which also appears to govern oneogenesis by the defective virus (Table V, R. Risser, unpublished observations), and each antigen is expressed on spleen colony-forming cells of the bone marrow (R. Risser, unpublished observations). The detailed parallels of FE and Abelson antigens encourage the belief that these similarities reflect general principles of murine leukemogenesis.
Summary
Serum from C57BL/6 (B6) mice hyperimmunized with NB-tropic Friend virus complex (FV) was cytotoxic for FV-induced erythroleukemic spleen cells and B6 Friend-murine leukemia virus (F-MuLV) lymphoma cells. Cytotoxic activity for erythroleukemia cells remained after repeated absorption of B6 anti-FV antiserum with Friend-Moloney-Rauscher MuLV lymphoma cells but was removed by absorption with erythroleukemia cells induced by FV or Rauscher virus. This serologic test system identified a previously unrecognized cell-surface antigen of mouse leukemia, designated Friend Erythroleukemia (FE) antigen to signify its appearance as a determinant of virally induced erythroleukemic differentiation. FE antigen was not detected on 15 transplanted or primary hematopoietic neoplasms, nor was it detected on cells infected with ecotropic, xenotropic, or dualtropic MuLV isolates in tissue culture. Two spleen focus-forming virus (SFFV) nonproducer cells of rats and one of mice express FE antigen in amounts comparable to primary erythroleukemia cells.
Absorption tests with FE typing serum indicated that FE antigen was expressed on bone marrow and spleen but not thymus, lymph node, or peripheral blood of uninfected AKR, BALB/c, DBA, and SWR mice; all five tissues from B6 and C57L were negative. Quantitative absorption tests indicated that the expression of FE antigen, though much lower than on erythroleukemic cells, was greatest on fetal liver, less on bone marrow, and lowest on spleen from BALB and SWR mice. Treatment of BALB/c or SWR fetal liver, bone marrow, spleen, thymus, or lymph node cells with FE typing serum did not result in significant lysis. These observations are consistent with the interpretation that FE antigen is expressed by a minor cell population present in fetal liver, bone marrow, and spleen. Expression of FE antigen, determined by absorption with bone marrow cells, cosegregated with inheritance of the Fv-2 s allele in the 17 inbred, 7 recombinant inbred, and 4 congenic mouse strains tested. In summary, the FE antigenic system identifies a cell-surface determinant that has the properties of a SFFV-specified antigen and hematopoietic differentiation alloantigen controlled by the Fv-2 locus. The similarity of FE antigen to Abelson antigen may provide insight into the pathogenic properties of defective transforming MuLV.
